Literature DB >> 6467798

Multiple-dose ciprofloxacin kinetics in normal subjects.

G E Aronoff, C H Kenner, R S Sloan, S T Pottratz.   

Abstract

To determine multiple-dose kinetics of the quinoline carboxylic acid derivative ciprofloxacin, we gave 12 normal subjects ciprofloxacin, 250 mg by mouth every 12 hr for 13 doses. Plasma concentrations were measured by HPLC after the first, seventh, and thirteenth doses. Peak and trough plasma concentrations were measured daily. Ciprofloxacin was rapidly absorbed from the gastrointestinal tract and reached maximum serum concentrations about 1 hr after dosing. Ciprofloxacin elimination t1/2 increased from 3.71 hr after the first dose to 6.51 hr after the thirteenth dose (P less than 0.05). Apparent plasma clearance decreased from 0.823 to 0.629 l/kg/hr because of decreased nonrenal clearance. Drug cumulation did not occur throughout the experiment. We conclude that concentrations of ciprofloxacin in excess of the minimum inhibitory concentrations for many important pathogens can be achieved in plasma and that controlled clinical trials of ciprofloxacin efficacy in selected systemic infections are warranted.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467798     DOI: 10.1038/clpt.1984.192

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Pharmacokinetics of ciprofloxacin in the elderly: increased oral bioavailability and reduced renal clearance.

Authors:  B Ljungberg; I Nilsson-Ehle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

2.  Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis.

Authors:  A Smith; A Weber; R Pandher; J Williams-Warren; M L Cohen; B Ramsey
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

3.  Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis.

Authors:  T A Golper; A I Hartstein; V H Morthland; J M Christensen
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

Review 4.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

5.  Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography.

Authors:  A J Groeneveld; J R Brouwers
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

6.  Pharmacokinetics and bactericidal activities of one 800-milligram dose versus two 400-milligram doses of intravenously administered pefloxacin in healthy volunteers.

Authors:  O Petitjean; B Pangon; N Brion; M Tod; C Chaplain; V Le Gros; K Louchahi; P Allouch
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Ciprofloxacin concentrations in tonsils following single or multiple administrations.

Authors:  N Falser; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

8.  Single and multiple dose pharmacokinetics of ciprofloxacin in gynecological tissues.

Authors:  G J Gerstner; A Dalhoff; H Weuta
Journal:  Infection       Date:  1988       Impact factor: 3.553

9.  Ofloxacin pharmacokinetics in mechanically ventilated patients.

Authors:  C Martin; D Lambert; B Bruguerolle; P Saux; J Freney; J Fleurette; H Meugnier; F Gouin
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.